Stay updated on Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page.

Latest updates to the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page revision tag was updated from v3.6.3 to v3.6.4, indicating a new version of the study record. This change is administrative and does not alter the study details or participant-facing information.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedFooter area now includes new institutional attributions for the Moffitt Cancer Center Clinical Trials website and related entities, and the revision tag in the footer has been updated from v3.6.2 to v3.6.3.SummaryDifference0.2%

- Check40 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a recent deployment of the ClinicalTrials.gov page. This update does not change the study details or any data presented on the page.SummaryDifference0.1%

- Check54 days agoChange DetectedPage now displays a recruitment status indicating no longer looking for participants and adds new reader guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) to help users understand and engage with the study. The Intervention/Treatment label is reformatted, and the site revision is updated to v3.6.0.SummaryDifference0.4%

- Check61 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, signaling a new published iteration of the page.SummaryDifference0.1%

- Check68 days agoChange DetectedThe footer branding and sponsor-related navigation text on the study page has been removed, changing how institutional affiliation and related links are presented at the bottom of the page.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page.